Related by context. All words. (Click for frequent words.) 68 dose escalation phase 67 rALLy trial 67 APEX AMI trial 66 Phase 2b kidney transplant 66 CLARITY study 66 PRIMO CABG 65 PEARL SC 65 MAGE A3 ASCI 64 XL# SAR# 64 HF ACTION 64 CHAMPION PCI 64 STRIDE PD 64 CALGB # [002] 64 riociguat 63 evaluating Actimmune 63 phase IIIb 63 CURE AF 63 thorough QT 63 PRECISE Trial 63 UPLYSO 63 MGCD# clinical trials 63 SUTENT ® 63 EMPHASIS HF trial 63 oral methylnaltrexone 63 MIST II 62 Fibrillex TM 62 Silenor NDA 62 oral ridaforolimus 62 ZOLINZA 62 budesonide MMX Phase III 62 tramiprosate Alzhemed TM 62 Phase 1a clinical 62 number NCT# ClinicalTrials.gov 62 phase IIb study 62 MEND CABG II 62 ACTIVE W 62 Zevalin consolidation 62 Phase IIb III 62 GENASIS clinical 62 phase IIa clinical 62 oxymorphone ER 62 LUMINATE 62 Recurrent Glioblastoma 62 MERLIN TIMI 62 confirmatory clinical 62 SIMPADICO 62 Onrigin 62 Zemplar Capsules 62 AVERROES 62 mild hepatic impairment 62 APEX PD 61 midstage clinical 61 TransVax ™ 61 Dacogen injection 61 Phase Ib IIa 61 phase IIa 61 Phase IIIb clinical 61 TEC #OL 61 CRMD# 61 samalizumab 61 EXPLORE Xa 61 mg/m2 cohort 61 randomized controlled multicenter 61 Plicera 61 Biologic License Application BLA 61 Anturol TM 61 lorcaserin Phase 61 multicenter Phase II 61 dose escalation clinical 61 phase Ib 61 relapsed MM 61 SPARLON 61 relapsed MCL 61 CLIRS trial 61 reduce serum phosphate 61 pivotal bioequivalence 61 BLA filing 61 treatment naive genotype 61 Cloretazine 61 randomized Phase IIb 61 ThermoDox ® clinical 61 ENABLE Phase 2 61 ALN VSP Phase 61 sargramostim 61 Phase Ib clinical 61 TASKi2 61 hoFH 60 CARE HF 60 Urocortin 2 60 subcutaneous PRO 60 trastuzumab DM1 T DM1 60 registrational 60 AVADO 60 randomized multicenter Phase III 60 MADIT II 60 PANVAC VF 60 neratinib 60 ENDEAVOR III 60 visit http:/www.clinicaltrials.gov/ 60 BENICAR HCT 60 Traficet EN 60 velafermin 60 Zenvia ™ 60 ACCORD Lipid 60 DSMB recommended 60 PRECISE trial 60 APPRAISE 60 Phase III HEAT 60 OvaRex ® MAb 60 ENDEAVOR IV 60 DEB# 60 randomized discontinuation trial 60 Phase Ib II 60 Randomized controlled 60 histamine dihydrochloride 60 Prosaptide 60 Bezielle 60 rhLF 60 Prostate AdenoCarcinoma Treatment 60 Hematide ™ 60 AIM HIGH 60 SUCCEED trial 59 SinuNase ™ 59 TOLAMBA 59 PDE# inhibitors 59 rALLy 59 lumiliximab 59 telaprevir VX 59 preclinical pharmacokinetic 59 Trofex 59 LibiGel ® testosterone gel 59 REVIVE Diabetes 59 dual antiplatelet 59 BRIM3 59 CHAMPION PLATFORM 59 CA9 SCAN 59 Phase Ib study 59 phase IIb clinical 59 PF # [002] 59 ISTODAX 59 Arranon 59 TASKi3 59 alvespimycin 59 Refractory Angina 59 BCIRG 59 Telintra 59 oral talactoferrin 59 CINQUIL 59 Tectin TM 59 endothelin antagonists 59 Tarceva TM 59 Corlux 59 OraTest R 59 Proellex TM 59 CIP TRAMADOL ER 59 phase IIb trial 59 Phase #b/#a 59 antiangiogenic therapy 59 TransVax 59 ICD therapy 59 EchoCRT 59 KRN# 59 GAMMAGARD 59 CUSTOM III 59 herpetic keratitis 59 ONTARGET 59 postapproval 59 Q#IR 59 CIMZIA TM certolizumab pegol 59 BRIM2 59 eprodisate Fibrillex TM 59 MYTHOS trial 59 Dr. McHutchison 59 APTIVUS ritonavir 59 DMEP 59 Phase IIB 59 Androxal TM 59 TransVax tm 59 GERD migraine headaches 59 LibiGel Phase III 59 Granisetron Hydrochloride Injection 59 acyclovir Lauriad R 59 TLK# 59 Premarket Approval 59 Phase #/#a 59 REMINYL ® 59 ongoing Phase 1b 59 GENASIS 59 Secondary efficacy endpoints 58 prelicensure 58 eritoran 58 unblinding 58 UVIDEM 58 balsalazide tablet 58 PFO migraine 58 MGd 58 Phase IIB clinical 58 cladribine tablets 58 Specifid 58 DASISION 58 ARCOXIA 58 Intervention Effectiveness 58 CEL SCI Phase III 58 NSABP C 58 IMC #B 58 HCD# [002] 58 PROTECT II 58 oral FTY# 58 desvenlafaxine 58 PARTNER Trial 58 dirucotide MBP# 58 PROMACTA CARES 58 ENRICH trial 58 relapsed ALL 58 placebo controlled multicenter 58 NP2 Enkephalin 58 PROCHYMAL 58 Phase III psoriasis 58 galiximab 58 pharmacokinetic pharmacodynamic 58 granted Ortec 58 Cimzia TM 58 elotuzumab 58 ABCSG 58 ANCHOR trial 58 COSIRA trial 58 Velcade bortezomib 58 PEGylated interferon beta 1a 58 ICON7 58 LibiGel NDA 58 Teriflunomide 58 INSPIRE Trial Phase III 58 NEUVENGE 58 Certolizumab pegol 58 initiate Phase IIa 58 HuMax EGFr 58 ORAL Sync 58 Phase III LibiGel 58 recurrent glioblastoma multiforme 58 ponatinib 58 MEND CABG 58 subcutaneous methylnaltrexone 58 assessing T DM1 58 CYT# QbG# 58 ONCONASE R 58 Trovax 58 lintuzumab SGN 58 Cloretazine R VNP#M 58 Phase #b/#a clinical 58 enzastaurin 58 Canvaxin 58 oral rivaroxaban 58 ZYBRESTAT fosbretabulin 58 PSMA ADC 58 ALSYMPCA 58 NDA resubmission 58 CIMZIA TM 58 ToGA 58 multicentre prospective 58 BLOOM DM 58 noninvasive outpatient 58 Genz # 58 IMPACT DCM clinical 58 Bifeprunox 58 bevirimat Study 58 Angiox ® 58 Allovectin 7 ® 58 ARIXTRA R 58 intensive lipid lowering 58 PEG SN# 58 Hedgehog antagonist 58 develop HBV reactivation 58 Neovasc Reducer 58 antiretroviral naïve 58 candidate CRLX# 58 unblind 58 EmbraceAC 58 Pyridorin 58 HDL Selective Delipidation 58 PA# [002] 58 Phase III ADT 58 Budesonide foam crofelemer 58 poststroke depression 58 sNDA submission 57 non nucleoside HCV 57 SYMMETRY trial 57 MVax R 57 BEXXAR Therapeutic Regimen 57 Orathecin 57 ruxolitinib 57 Aryplase 57 Stimuvax R 57 Egrifta 57 EMPOWER TM 57 desvenlafaxine succinate 57 FIX HF 5 57 Phase III randomized controlled 57 AMPAKINE CX# 57 Carotid Revascularization Endarterectomy vs. 57 Crofelemer budesonide foam 57 specified primary endpoint 57 Simulect 57 rALLy clinical trial 57 recurrent metastatic ovarian cancer 57 initiate Phase 1b 57 resectable pancreatic cancer 57 evaluating tivozanib 57 BARI 2D 57 Diamyd r 57 PDX pralatrexate 57 DES implantation 57 ongoing Phase IIIb 57 TRO# 57 Targretin capsules 57 Octreolin 57 NATRECOR ® 57 r hGH 57 ADVERSE EVENTS 57 dacetuzumab 57 Thorough QT 57 vismodegib 57 OvaRex R 57 RSD# oral 57 multicenter randomized Phase 57 viral kinetic 57 BHT DNA 57 Phase 1b trial 57 NeuroStar TMS Therapy 57 Cloretazine ® 57 designated HVTN 57 Saforis 57 CIMZIA ™ 57 interferon gamma 1b 57 novel oral anticoagulant 57 Phase lll 57 prospective observational studies 57 HIV coinfected 57 Alzhemed TM 57 Sanofi Acomplia 57 vosaroxin 57 Neo Kidney Augment 57 indiplon capsules 57 RSR# 57 Pruvel 57 blinded randomized placebo controlled 57 PRIMO CABG2 57 Phase III TRIST 57 NeuroVax 57 evaluating T DM1 57 viral kinetics 57 ACTEMRA TM 57 TBC# 57 Dr. Gulfo 57 Pegloticase 57 Triapine R 57 Prestara 57 ocrelizumab 57 Active Ulcerative Colitis 57 Wyeth Progenics 57 GENASIS trial 57 nonclinical studies 57 PERSEUS 57 NV1FGF 57 relapsing remitting MS RRMS 57 ExCell study 57 EXJADE 57 CONBRIZA 57 Evoltra 57 placebo controlled clinical 57 thrombin inhibiting aptamer 57 Bystolic nebivolol 57 secondary efficacy endpoint 57 adjuvant GIST 57 omacetaxine mepesuccinate 57 IL# PE#QQR 57 Empatic ™ 57 nab paclitaxel 57 rheumatoid arthritis osteoarthritis ankylosing 57 GetGoal Phase III 57 PROPEL trial 57 Fx #A 57 Vaxfectin ® 57 Aflibercept 57 multicenter randomized controlled 57 vidofludimus 57 YONDELIS 57 ARIXTRA 57 Prospective Randomized 57 ILLUMINATE 57 PROTECT AF 57 IMA# 57 torsemide ER 57 EMPOWER ™ 57 ACAPODENE TM 57 Albuferon Phase 57 lomitapide 57 Primary endpoints 57 Phase III multicenter 57 Surfaxin LS 57 follicular Non Hodgkin 57 phase IIb 57 ganaxolone 57 genomic biomarker 57 ACAPODENE 57 Teysuno 57 StemEx R 57 NOX E# 57 Ocrelizumab 57 ritonavir boosted danoprevir 57 R lenalidomide 57 phase IIb III 57 pain palliation 57 CATIE AD 57 postexposure prophylaxis 57 ATACAND 57 tolevamer 57 PrevOnco ™ 57 containing LABAs 57 EMBEDA TM 57 registrational Phase 57 tanespimycin 57 postoperative chemotherapy 57 maximally tolerated dose 57 BioNumerik 57 lintuzumab 57 Zelnorm Zelmac 57 Bayer HealthCare Onyx Pharmaceuticals 56 ASSERT trial 56 PrevOnco 56 novel therapeutic antibodies 56 mertansine 56 recurrent herpes labialis 56 Cladribine tablets 56 primary humoral immunodeficiency 56 HuCAL antibodies 56 resultsof 56 Tykerb lapatinib 56 placebo controlled Phase III 56 Sunesis Pharma 56 IMPACT DCM 56 NATRECOR R 56 refractory CLL 56 Motesanib 56 MyVax personalized immunotherapy 56 curative surgical resection 56 TRIST 56 please visit www.advaxis.com 56 Amoxicillin PULSYS Phase III 56 ACCEDE 56 EMBEDA ™ 56 ORBIT II 56 Phase III metastatic melanoma 56 HCV polymerase 56 TAXUS VI 56 STEP BD 56 TORISEL 56 asymptomatic hyperuricemia 56 ELACYT 56 REALITY Trial 56 azilsartan medoxomil 56 Bicifadine 56 EMPHASIS HF 56 HuMax TAC 56 palifermin 56 Virulizin ® 56 Vertex hepatitis C 56 IMiDs ® compound 56 Pulminiq 56 ASCEND HF 56 im peramivir 56 R roscovitine 56 DermaVir Patch 56 Subgroup analysis 56 Intermezzo ® NDA 56 nalbuphine ER 56 sapacitabine CYC# 56 canakinumab 56 EOquin TM 56 NSABP B 56 cathepsin K inhibitor 56 BEXXAR therapeutic regimen 56 randomized discontinuation 56 Nuvion 56 Dose escalation 56 IND CTA 56 prednisone prednisolone plus 56 Canvaxin TM 56 SEASONIQUE 56 Troxatyl TM 56 Triolex 56 Panzem R NCD 56 phase Ib clinical 56 oncolytic virus therapies 56 durable pain palliation 56 elacytarabine 56 PSN# [002] 56 NeuroFlo 56 successfully commercialize Iluvien 56 HepeX B TM 56 SPRIX ® 56 oral deforolimus 56 receiving immunosuppressive therapy 56 Rasilamlo 56 smoldering multiple myeloma 56 Diamyd r vaccine 56 Zenvia Phase III 56 EDEMA3 56 Phase #/#a trial 56 Corgentin 56 anagrelide 56 humanised monoclonal antibody 56 Phase III VISTA 56 PREVENT IV 56 Augment Injectable 56 methotrexate therapy 56 OPT CHF 56 Plenaxis TM 56 ATPace TM 56 IFN alpha XL 56 NEO3 56 LEVADEX ™ 56 Val HeFT 56 hyperphenylalaninemia HPA due 56 tramiprosate ALZHEMED TM 56 commercialize CorMedix drug 56 CCR5 receptor antagonist 56 RIGScan CR 56 recurrent malignant glioma 56 regorafenib 56 prospectively defined 56 treats acute lymphoblastic 56 Luveris 56 antioxidant supplementation 56 O PPDS 56 fosbretabulin 56 pomalidomide 56 faropenem medoxomil 56 Afatinib 56 Restanza TM 56 lenalidomide Revlimid R 56 thalidomide Thalomid 56 OncoVex 56 PROSTVAC TM 56 oral prednisolone 56 Hypertensive adverse reactions 56 hypersensitivity allergic reactions 56 Embolic Protection Device 56 Acute Decompensated Heart Failure 56 confirmatory Phase IIIb 56 XOMA 3AB 56 EDARBI 56 KIACTA ™ 56 EVIZON TM squalamine lactate 56 pediatric pontine glioma 56 Immunotherapeutic 56 paclitaxel poliglumex 56 triple nucleoside 56 VALOR trial 56 AA Amyloidosis 56 FLUARIX 56 Omigard 56 Initiates Phase III 56 oral picoplatin 56 isatoribine 56 REVIVE TA 56 clevidipine 56 NEUMUNE 56 orBec 56 Liposomal Grb 2 56 clazosentan 56 multicenter Phase 56 CEQ# 56 sunitinib malate 56 QuadraSphere 56 pemetrexed Alimta 56 MelaFind ® 56 Exforge HCT 56 AFRS TM 56 Phase IIb trials 56 lupus renal disease 56 Aurexis 56 clevudine 56 Initiates Enrollment 56 lipoprotein lipase deficiency LPLD 56 Poly ICLC 56 boards IRBs 56 CAMMS# 56 SAR# [004] 56 Clinicaltrials.gov 56 inhaled AAT 56 oral prodrug 56 Allovectin 7 56 FavId 56 PRESEPT 56 Tesmilifene 56 QLT Plug Delivery 56 Phase IIIb study 56 fusion enhancers 56 senicapoc 56 GSK# [001] 56 Urocidin 55 CVac 55 AGHD 55 Pre IND 55 multicentre randomized 55 PEG PAL 55 biologic antibody 55 undergoing Percutaneous Coronary 55 pharmacodynamic markers 55 ritonavir boosted protease inhibitor 55 Levulan ® PDT 55 RE MODEL 55 recombinant interferon 55 PLCO 55 oocytes retrieved 55 cytoreductive nephrectomy 55 Aeolus Pharmaceuticals Announces 55 Raloxifene STAR 55 ATIR 55 neuropsychiatric events 55 recurrent metastatic 55 adjuvant endocrine therapy 55 Vorapaxar 55 R# #mg BID 55 Subgroup analyzes 55 dexanabinol 55 RX ACCULINK 55 Dr. Tashkin 55 Liraglutide Effect 55 midstage trials 55 Emtriva Viread 55 motesanib 55 Raptiva r 55 ABSORB clinical 55 ATPace 55 autologous cellular immunotherapy 55 Maximum Tolerated Dose 55 atherosclerotic renal artery stenosis 55 VITAL Trial 55 enoximone 55 MAXY alpha 55 biostatistical analysis 55 Cloretazine R 55 nonrandomized 55 oral mTOR inhibitor 55 reversing heparin 55 EndoTAGTM 1 55 IMPACT DCM trial 55 BEZ# 55 budesonide foam 55 Vitaxin 55 Exelbine NDA 55 brivaracetam 55 EDEMA3 trial 55 paclitaxel Taxol R 55 recombinant PSMA vaccine 55 MyVax 55 Sibutramine Cardiovascular Outcomes 55 myocardial revascularization 55 OncoGel 55 tropism testing 55 apricitabine ATC 55 remission CR 55 COSTAR II 55 intradermal injections 55 Stage IIB 55 zoledronic acid Reclast 55 confirmatory Phase III 55 Complete Response 55 forodesine 55 MGN# 55 Troxatyl 55 Azedra 55 motesanib diphosphate 55 pulls Darvon painkiller 55 cUTI 55 PROMACTA 55 evaluating satraplatin 55 genotypic resistance 55 Orosi Mill project 55 TACI Ig 55 glucocorticoid induced osteoporosis 55 coadministration 55 initiate multicenter 55 prospectively stratified 55 Dextofisopam 55 biologic DMARDs 55 MEVACOR 55 Medidur FA 55 CIMZIA R 55 vitro dissolution 55 Asentar 55 dose cohort 55 prospective multicentre 55 refractory colorectal cancer 55 confirmatory pivotal 55 preclinical efficacy 55 HuLuc# 55 GnRH antagonist 55 crizotinib PF # 55 valopicitabine NM# 55 FOSRENOL ® 55 Apoptone 55 Spiegelmer ® 55 TRA 2P 55 Phase Ia 55 CALGB 55 ChronVac C 55 laromustine 55 multicenter multinational 55 Presentence 55 modified REGENESIS Phase IIb 55 Nasulin ™ 55 Intravenous immunoglobulin 55 Mepact 55 Aplidin 55 DPX Survivac 55 HuMax HepC 55 AVN# Phase 55 opioid naive 55 pharmacodynamics PD 55 multicenter phase 55 eculizumab therapy 55 LPLD 55 Forodesine HCl 55 subcutaneous ORENCIA 55 Voraxaze ™ 55 NCT# ClinicalTrials.gov 55 PI3K/Akt pathway inhibitor 55 HYVET 55 Lofexidine 55 Phase 2a clinical trials 55 Initiated Phase 55 hereditary deficiency 55 Mark A. Sirgo 55 Submits Response 55 KRYSTEXXA TM 55 GALNS 55 multicenter prospective 55 pixantrone NDA 55 MelaFind pivotal 55 Thalomid ® 55 JAK2 Inhibitor 55 Ganite ® 55 BrachySil TM 55 ExTRACT TIMI 55 Airway Bypass 55 Phase 2a trial 55 EFAPROXYN 55 TOCOSOL Paclitaxel 55 APTIVUS 55 iii GTx 55 SPRYCEL ® 55 lipid lowering therapy 55 maximal doses 55 Phase #b/#a trial 55 SNS# T 55 dose titration 55 BETAS 55 patientswith 55 atacicept 55 GRAVITAS trial 55 Trobalt 55 Rilonacept 55 Plenaxis R 55 Extina 55 GRNVAC1 55 Hepatocellular Carcinoma HCC 55 Phase 1b clinical 55 HyQ 55 visilizumab 55 aflibercept 55 efficacy endpoint 55 urocortin 2 55 class mGluR5 inhibitor 55 Tumor Response 55 IND Investigational New 55 PHASE III 55 Xcellerated T Cells 55 delivers fluocinolone acetonide FA 55 GLPG# 55 RECORD1 55 symptomatic hyponatremia 55 opioid bowel dysfunction 55 journal Gynecologic Oncology 55 naïve HCV 55 RRMS patients 55 LymphoStat B TM 55 dose escalation Phase 55 divalproex sodium 55 HuMax 55 MediGene focuses 55 ACCLAIM COPD 55 visceral metastases 55 CURRENT OASIS 7 55 Multiple Ascending Dose 55 Phase 2b RESTORE CLI 55 patients receiving myelosuppressive 55 isavuconazole 55 FRDA 55 apoptosis inducer 55 pharmacokinetic PK study 55 placebo controlled Phase 55 KRYSTEXXA TM pegloticase 55 basal insulin analogue 55 Oral NKTR 55 prucalopride 55 bacillus Calmette Guerin BCG 55 Linjeta TM 55 Phase IIb clinical trials 55 CCR5 antagonist 55 Approvable letter 55 ARIKACE ™ 55 periodically reassessed 55 Peginterferon alfa 2b 55 Known hypersensitivity 55 liposomal formulation 55 R#/MEM # 55 symptomatic paroxysmal AF 55 Committee IDMC 55 neurologic progression 55 Elocalcitol 55 Dacogen TM 55 GLP1 agonist 55 ofatumumab HuMax CD# 55 Onrigin TM 55 tocilizumab 55 Bionutrics 55 guanfacine extended release 55 postmarketing adverse 55 rindopepimut 55 BLOOM Behavioral modification 55 Aggrastat ® tirofiban hydrochloride 55 Meta analyzes 55 OvaRex 55 Study #CL# 55 Liver transplantation 55 de novo kidney transplant 55 Nabi HB Intravenous 55 exploratory Phase IIa 55 TOCOSOL Camptothecin 55 compound INCB# 55 myelodysplastic myeloproliferative diseases 55 Matrix Phase 2b 54 Ceplene/IL-2 54 CoreValve System 54 Aplenzin 54 evaluating Prochymal 54 Phase IIa trials 54 AQUAVAN R 54 TroVax ® 54 coronary stent merged 54 beta 1a 54 Pafuramidine 54 cariprazine 54 Severe Sepsis 54 candidate REP# 54 HORIZONS AMI 54 ICD implantation 54 AChE inhibitors 54 RE SURGE 54 microbiologically evaluable 54 stratifying patients 54 HGS ETR1 mapatumumab 54 acetonide FA 54 bardoxolone methyl 54 LymphoStat B Phase 54 Febuxostat 54 SILENOR ™ 54 Confirmatory tests 54 Certican 54 TEMSO 54 Aurora kinase inhibitor 54 PolyHeme ® 54 multicenter randomized Phase III 54 Hematide ™ peginesatide 54 ovarian cancer chronic hepatitis 54 GATTEX ™ 54 antiplatelet medications 54 QOPI 54 obatoclax 54 Harry Palmin President 54 IMiDs R 54 metastatic malignant 54 Quinamed 54 EGS# 54 Marketing Authorisation Holders 54 reboxetine 54 CYT# potent vascular disrupting 54 blinded randomized controlled 54 pharmacodynamic properties 54 adecatumumab MT# 54 E2F Decoy 54 mycophenolate mofetil MMF 54 Cytolin 54 torcetrapib atorvastatin 54 multicenter randomized clinical 54 Amplimexon 54 evaluating REVLIMID 54 clinico pathological 54 psoriatic arthritis PsA 54 NSABP 54 NasalFent 54 deforolimus 54 Severe hypersensitivity reactions 54 percutaneous cryoablation 54 GVAX Pancreas Vaccine 54 kidney urologic 54 bolus dose 54 GOUT 54 APPROVe trial 54 PLX STROKE targeting 54 dosing cohort 54 undergone splenectomy 54 lesinurad 54 mITT population 54 MADIT 54 blinded randomized 54 optimal dosing 54 Cinquil 54 Valdoxan 54 Excellarate TM 54 systemic immunosuppressive drugs 54 please visit http:/www.sunesis.com 54 endoscopic gastric ulcers 54 venous thromboembolic disease 54 CALERIE 54 Phase III Psoriasis 54 demonstrated antitumor activity 54 randomized Phase 2b 54 IND submission 54 evaluable subjects 54 Sycrest 54 methylnaltrexone 54 antiarrhythmic drug 54 elective percutaneous coronary 54 Daxor 54 morphometric vertebral fractures 54 bepotastine besilate nasal spray 54 http:/www.repligen.com 54 RESTORE CLI 54 CRp 54 Investigational Device Exemption 54 RUGs IV 54 ENGAGE AF TIMI 54 omega interferon 54 generation purine nucleoside 54 Ixempra 54 vivo coagulation 54 VBLOC TM 54 Kahalalide F 54 FASLODEX 54 PENNVAX B 54 PIX# trial 54 MelaFind R 54 glatiramer acetate Copaxone 54 Muraglitazar 54 pharmacologic stress 54 lenalidomide Revlimid 54 Demonstrates Sustained 54 rFVIIa 54 IONSYS TM 54 HepeX B 54 nosocomial pneumonia NP 54 dipyridamole plus 54 Avastin adjuvant 54 LAB CGRP 54 CMV vaccine 54 rtPA 54 R vitespen 54 agalsidase alfa 54 antithrombotic therapy 54 weekly subcutaneous injections 54 OVATURE 54 thorough QTc 54 TG MV 54 bardoxolone 54 dose intramuscular 54 E1 INT TM 54 TNF inhibitor therapy 54 developing ViaCyte SM 54 PREGNANT Study 54 guideline concordant 54 QTinno 54 StemEx 54 GEM OS1 54 prospective multicenter randomized 54 Advaxis Phase 54 Board DSMB 54 THALOMID 54 JAK#/JAK# inhibitor CYT# 54 Adventrx 54 serum phosphorous 54 Onyx Pharmaceuticals Announces 54 carotid endarterectomy CEA 54 Cethrin 54 posaconazole 54 XL# anticancer compounds 54 Alvesco R